Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gregory Duncan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 1.83
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -0.72
Financials
Net Income
$-11.53MEBITDA
$-4.86MFree Cash Flow
$-3.61MEPS (diluted)
$-0.34Shares Outstanding (diluted)
34.13M+17556.4%Operating Expenses
$4.86MCash & Debt
$9.61MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-34.26M | $-4.32 |
| 2024 | $0.00 | $-12.35M | $-12.52 |
| 2023 | $0.00 | $-5.30M | $-7.05 |
| 2022 | $0.00 | $-12.25M | $-27.66 |
| 2021 | $0.00 | $-15.96M | $-47.90 |
| 2020 | $0.00 | $-10.35M | $-52.50 |
| 2019 | $0.00 | $-2.47M | $-12.80 |
| 2018 | $0.00 | $-2.11M | $-10.93 |
Valuation
DWTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·34d ago·Positive
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
View source ↗ - Newsmarketbeat.com·34d ago·Positive
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment Dogwood Therapeutics NASDAQ: DWTX said its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients and is expected to report top-line data later this fall.
View source ↗ - Newsglobenewswire.com·54d ago·Positive
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.15 per share
Typical surprise -142.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.34 vs $-0.14miss
- Thu, May 14$-0.15 vs $-0.22beat
- Wed, Mar 18$-0.26 vs $-0.86beat
- Thu, Nov 6$-8.20 vs $-1.23miss
- Wed, Aug 13$-1.99 vs $-1.26miss
- Thu, May 8$-8.45 vs $-0.77miss
Estimates and results for DWTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DWTX officers and directors.
No open-market trades in the recent filings. All 38 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
38 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DWTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.